Facebook Inc. (FB): Swinging for a Q4 Earnings Home Run?

Page 1 of 2

Facebook Inc. (NASDAQ:FB) has certainly garnered some attention with its recovery from about $19 per share over the last two months. The stock is only a few dollars away from being named Phoenix-book – having come back from the ashes where it started at $38 per share last May and by the fall was down more than 50 percent. Now, with the company due to report its quarterly earnings after the bell Wednesday, has the recent momentum and introduction of new features in the past few weeks translate into its earnings report?

Facebook Inc. (NASDAQ:FB) is facing Wall Street expectations of reporting revenue of $1.52 billion and an EPS of 15 cents. When the report comes out Wednesday afternoon, chances are analysts and investors will be looking at the progress Facebook might have made in monetization, considering that the company reports that 60 percent of its one billion users access Facebook via mobile devices. Also, they will probably be listening in on the earnings call after the reports is released, to see if CEO Mark Zuckerberg addresses the future of Graph Search. There seems to be great potential behind this, and some think that Graph Search may be competitive with Google Inc. (NASDAQ:GOOG) Search.

Facebook Inc. (FB)Besides Graph Search, Facebook Inc. (NASDAQ:FB) has been progressing over the last couple of months, developing several new features, and tht has apparently fueled some of this momentum in the stock. There is the pay-per-message service, where users can spend $1 to send a message to someone on the network who is not in their friends circle (a friend of a friend, or a hiring manager at some company when you’re on a job hunt, for example), or $100 to send a message directly to an executive at Facebook, including Zuckerberg.

Another new feature is corralling speculation about a phone.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!